Tam Thornton
Director of Investor Relations
Replay available
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Q4 2025 earnings conference call, held 2026-02-25. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Doug Ingram
Chief Executive Officer
Patrick Moss
Chief Commercial Officer
Dr. Louise Rodino-Claypack
Executive Vice President, Research & Development
Ryan Wong
Chief Financial Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Sarepta Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.818 Good afternoon and welcome to Sarepta's fourth quarter 2025 00:00:04.818 -- 00:00:09.986 earnings results call. As a reminder, today's program is being recorded. 00:00:09.986 -- 00:00:14.693 At this time, I'll turn the call over to Tam Thornton, Sarepta's Director of Investor 00:00:14.693 -- 00:00:18.055 Relations. Please go ahead. 00:00:18.359 -- 00:00:22.465 Thank you, Operator, and thank you all for joining today's call. 00:00:22.465 -- 00:00:27.554 Earlier this afternoon, we released our financial results for the fourth quarter of 2025. 00:00:27.554 -- 00:00:31.541 The press release and slides are available on the investor section of our website at 00:00:31.541 -- 00:00:36.790 Sarepta.com, and our 10-K will be filed with the Securities and Exchange Commission next 00:00:36.790 -- 00:00:40.636 Monday. Joining us on the call today are Doug Ingram, Dr. 00:00:40.636 -- 00:00:44.984 Louise Rodino-Claypack, Patrick Moss, and Ryan Wong. 00:00:44.984 -- 00:00:49.091 After our formal remarks, we'll open the call for Q&A. 00:00:49.091 -- 00:00:52.797 I'd like to note that during this call, we will be making a number of forward-looking 00:00:52.797 -- 00:00:57.269 statements, Please refer to slide two on the webcast, which contains our forward-looking 00:00:57.269 -- 00:01:01.854 statements. These forward-looking statements involve risks and uncertainties, many of 00:01:01.854 -- 00:01:06.598 which are beyond Surreptice control. Actual results could materially differ from these 00:01:06.598 -- 00:01:10.783 forward-looking statements, and any such risks can materially and adversely affect the 00:01:10.783 -- 00:01:16.028 business, the results of operations, and trading prices for Surreptice common stock. 00:01:16.028 -- 00:01:19.912 For a ...